secwatch.observer — SEC 8-K summary
======================================

Issuer:     ACURA PHARMACEUTICALS, INC (—)
CIK:        0000786947
Form:       8-K
Filed at:   2026-11-03T13:20:04+00:00
Accession:  0001104659-26-121685
Event type: debt
Sentiment:  negative
Materiality: 0.82
Item codes: 1.01, 2.01, 2.03, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Acura Pharmaceuticals borrows $141,607 from AD Pharma; note balance hits $11.44M with going-concern warning
--------------------------------------------------------------------------------

- Two new loans of $41,607 (Oct 19, 2026) and $100,000 (Oct 30, 2026) from Abuse Deterrent Pharma bring the secured note principal to $11,435,886.
- Accrued interest is approximately $1,416,000 as of October 31, 2026; the note bears 5.25% interest, rising to 7.5% on overdue amounts.
- Acura says without additional financing by late-November 2026 it must furlough or lay off employees, terminate operations, or seek bankruptcy protection.
- AD Pharma agreement requires FDA acceptance of an NDA for LTX-03 by December 31, 2026, and payoff of the secured note by the same date.
- Loan #66 of $100,000 on October 2, 2026 preceded the two disclosed loans; total aggregated principal rose from $2,319,279 in November 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/786947/000110465926121685/0001104659-26-121685-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/786947/000110465926121685/tm2628790d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-121685

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer